Renaissance Technologies’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-118,488
| Closed | -$3.22M | – | 3305 |
|
|
2025
Q4 | $3.22M | Sell |
118,488
-76,100
| -39% | -$2M | 0.01% | 1599 |
|
|
2025
Q3 | $5.03M | Buy |
194,588
+13,200
| +7% | +$306K | 0.01% | 1489 |
|
|
2025
Q2 | $3.69M | Buy |
181,388
+34,800
| +24% | +$677K | ﹤0.01% | 1714 |
|
|
2025
Q1 | $2.66M | Buy |
146,588
+10,000
| +7% | +$223K | ﹤0.01% | 1818 |
|
|
2024
Q4 | $3.45M | Buy |
+136,588
| New | +$3.71M | 0.01% | 1680 |
|
|
2024
Q3 | – | Sell |
-42,788
| Closed | -$1.58M | – | 3563 |
|
|
2024
Q2 | $1.58M | Sell |
42,788
-269,682
| -86% | -$10.2M | ﹤0.01% | 2022 |
|
|
2024
Q1 | $13.1M | Buy |
+312,470
| New | +$12.8M | 0.02% | 848 |
|
|
2022
Q4 | – | Sell |
-25,888
| Closed | -$728K | – | 4142 |
|
|
2022
Q3 | $728K | Buy |
+25,888
| New | +$794K | ﹤0.01% | 2692 |
|
|
2021
Q4 | – | Sell |
-161,276
| Closed | -$8.71M | – | 3933 |
|
|
2021
Q3 | $8.71M | Sell |
161,276
-202,751
| -56% | -$9.51M | 0.01% | 1118 |
|
|
2021
Q2 | $12.2M | Sell |
364,027
-177,400
| -33% | -$4.87M | 0.02% | 1040 |
|
|
2021
Q1 | $11.2M | Sell |
541,427
-507,400
| -48% | -$11.7M | 0.01% | 1125 |
|
|
2020
Q4 | $18.4M | Sell |
1,048,827
-687,848
| -40% | -$12.4M | 0.02% | 805 |
|
|
2020
Q3 | $25.8M | Buy |
1,736,675
+99,500
| +6% | +$1.17M | 0.03% | 616 |
|
|
2020
Q2 | $21.3M | Buy |
1,637,175
+466,988
| +40% | +$2.07M | 0.02% | 785 |
|
|
2020
Q1 | $1.94M | Buy |
1,170,187
+54,819
| +5% | +$124K | ﹤0.01% | 2066 |
|
|
2019
Q4 | $2.49M | Buy |
1,115,368
+89,083
| +9% | +$207K | ﹤0.01% | 2212 |
|
|
2019
Q3 | $2.19M | Buy |
1,026,285
+114,000
| +12% | +$264K | ﹤0.01% | 2236 |
|
|
2019
Q2 | $2.44M | Buy |
912,285
+367,179
| +67% | +$1.25M | ﹤0.01% | 2223 |
|
|
2019
Q1 | $2.68M | Buy |
545,106
+102,625
| +23% | +$540K | ﹤0.01% | 2162 |
|
|
2018
Q4 | $1.31M | Buy |
442,481
+86,241
| +24% | +$424K | ﹤0.01% | 2446 |
|
|
2018
Q3 | $2.41M | Buy |
356,240
+74,861
| +27% | +$524K | ﹤0.01% | 2185 |
|
|
2018
Q2 | $2.13M | Buy |
281,379
+271,085
| +2,633% | +$3.62M | ﹤0.01% | 2234 |
|
|
2018
Q1 | $360K | Buy |
+10,294
| New | +$399K | ﹤0.01% | 3007 |
|
|
2017
Q4 | – | Sell |
-13,414
| Closed | -$575K | – | 3349 |
|
|
2017
Q3 | $575K | Sell |
13,414
-9,827
| -42% | -$368K | ﹤0.01% | 2750 |
|
|
2017
Q2 | $861K | Sell |
23,241
-90,621
| -80% | -$4.01M | ﹤0.01% | 2610 |
|
|
2017
Q1 | $6.17M | Buy |
113,862
+33,881
| +42% | +$1.76M | 0.01% | 1540 |
|
|
2016
Q4 | $4.25M | Sell |
79,981
-3,900
| -5% | -$222K | 0.01% | 1775 |
|
|
2016
Q3 | $5.08M | Buy |
83,881
+32,094
| +62% | +$2M | 0.01% | 1591 |
|
|
2016
Q2 | $3.41M | Sell |
51,787
-2,435
| -4% | -$155K | 0.01% | 1862 |
|
|
2016
Q1 | $3.07M | Buy |
+54,222
| New | +$6.1M | 0.01% | 1957 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Renaissance Technologies's CLDX Position: Q1 2026 in Review
Renaissance Technologies sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 118,488 shares — an estimated $3.22M sold.
Renaissance Technologies first reported a position in CLDX in Q1 2016 and held it in 30 quarters. The position peaked at $25.8M in Q3 2020. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Renaissance Technologies reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
- Renaissance Technologies sold 118,488 Celldex Therapeutics shares in Q1 2026, an estimated $3.22M.
- Renaissance Technologies first reported a position in Celldex Therapeutics in Q1 2016 and held it in 30 quarters.
- Renaissance Technologies's Celldex Therapeutics position peaked at $25.8M in Q3 2020.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.